Multi-center, Open-label, 24-week Study to Demonstrate the Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin 50/500 or 50/1000 mg Twice Daily in Patients With T2DM Inadequately Controlled With Metformin.
Phase of Trial: Phase IV
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Vildagliptin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 03 May 2012 Actual patient number 161 added as reported by ClinicalTrials.gov.
- 03 May 2012 Actual end date (October 2011) added as reported by ClinicalTrials.gov.